REGULATORY

• Eisai’s EZH2 Inhibitor Up for PAFSC Review on May 28
  May 17, 2021

• Daiichi Sankyo CEO Urges Rethink of Vaccine Approval System
  May 17, 2021

• LDP Project Team Urges Overhaul of Unpredictable Pricing System: Proposal
  May 14, 2021

• LDP Panels Call for Emergency Approval Process, Eyes Japan Made Vaccines
  May 14, 2021

• No Serious Safety Concerns Detected for Comirnaty: MHLW Safety Panels
  May 14, 2021

• 1st Oral SMA Med Risdiplam Up for PAFSC Review on May 26
  May 14, 2021

• Pharma Groups Want Price Maintenance for Patented Meds, Payer Sees It “Natural” to Rectify Gap: Chuikyo
  May 13, 2021

• Chuikyo OKs Re-Pricing for Tecentriq, Vyndaqel; 3 I/O Peers Challenge Cuts in Vain
  May 13, 2021

• Operating Profit Rate for Cost-Based Method Updated to 15.5%: Chuikyo
  May 13, 2021

• Novo’s Growth Hormone, Teijin’s Osteoporosis Med Skip May Listing
  May 13, 2021

• May Listing OK’ed for Darzquro, Pemazyre, Vitrakvi, Kesimpta and More
  May 12, 2021

• Ultomiris Faces 4.3% Price Cut under CEA Scheme
  May 12, 2021

• Breyanzi to Join NHI List on May 19 at Post-CEA-Adjusted Kymriah Price
  May 12, 2021

• Tecentriq, 3 I/O Rivals Face Quarterly Re-Pricing; Price Cuts Yet Again for Opdivo, Keytruda
  May 11, 2021

• Kanmin Taiwa Public-Private Confab Set for May 17
  May 11, 2021

• MHLW to Fund 7 Development Projects for COVID-19 Therapies
  May 11, 2021

• Japan in Talks with 3 Vaccine Makers for Additional Supplies, Eyes 250 Million More Doses
  May 10, 2021

• No Impact of Transport Seen on Comirnaty’s mRNA Content or Expression of Spike Proteins: NIHS Study
  May 10, 2021

• New Industry Vision to Reaffirm Pharmaceuticals as Growth Industry: MHLW Director
  April 30, 2021

• MHLW to Set New Generic Target of 80% in Every Prefecture by FY2023-End
  April 30, 2021

ページ

• « 先頭
• ‹ Prev
• …
• 150
• 151
• 152
• 153
• 154
• 155
• 156
• 157
• 158
• …
• Next ›
• 最終 »